{"text_format":"1","workbook":"xlsx","n_sheets":1,"sheets":["Page 17"],"not_rendered":{"charts":0,"images":0,"macros":1,"external_links":1,"defined_names":17,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"Page 17","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,0,0,4],[2,0,2,4]]}
["Table 12: PBS Other - Summary of direct payments and advances"]
[]
["Expenditure Year ending June 2009, 2010, 2011 and 2012 - $ millions"]
[null," 2008/09\n $ m "," 2009/10\n $ m "," 2010/11\n $ m "," 2011/12\n $ m "]
["Highly specialised drugs",750.7,858.5,1014.8355080700001,1194.9516654900001]
["Safety net card issue fees",8.3000000000000007,8.5,8.8954766999999997,9.0681059399999988]
["Drs Bag items",16,15,15.617141119999999,13.436973]
["Opiate Dependence Treatment Program",29.8,33.1,36.877697850000004,39.718899729999997]
["Special Authority Program",76,81.7,77.323529640000004,78.157280249999999]
["Chemotherapy Access Program ",67.7,83.8,94.764560590000002,219.82205356999998]
["Aboriginal health services (GST exclusive)",35.1,38.4,42.958939299999997,48.625698840000005]
["Botulinum Toxin Program (incl. Dysport)",10.3,12.8,13.55309875,14.79207001]
["Paraplegic and Quadriplegic Program",0.5,0.5,0.59100834999999996,0.56115569999999992]
["In vitro fertilisation",63.8,75,70.73831036,79.107694209999991]
["Human growth hormones",23,25.3,27.395636230000001,27.929236499999998]
["Other",0.2,0.1,0.12486360000000001,0.13304825000000001]
["Total  ",1081.4000000000001,1232.7,1403.6757705600003,1726.3038814900001]
[]
["Note: Expenditure figures refer to payments made through Medicare Australia and directly from the Department."]